Approximately 15–20% of breast cancer cases belong to the triple-negative breast cancers subtype (TNBCs), which is known to be the most aggressive subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 amplification [36,37]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.